Tagged Articles

Bayer 288 articles

J&J faces more potential million-dollar product liability judgments in 2017

johnsonandjohnson

The world’s largest health care company, Johnson & Johnson, was slapped with six of the seven largest product liability verdicts in 2016, and 2017 is shaping up to be just as woeful with the company facing potential verdicts totaling into the hundreds of millions of dollars. J&J faces at least 17 state and federal trials this year involving serious injuries and deaths allegedly caused by the company’s pharmaceuticals, medical devices, and consumer products. Last year the company was hit with a $1 billion judgment over faulty hip implants, a $72 million verdict involving ovarian cancer claims with Johnson’s baby powder, and ... Read More

Bayer invests in blood thinner with less bleeding risks than blockbuster Xarelto

xarelto

Pharmaceutical giant Bayer is partners with Johnson & Johnson’s Janssen Pharmaceuticals in the manufacturing and marketing of the blockbuster blood thinner Xarelto. But the company is investing millions to develop a competitor product that has the potential to be safer and more effective at preventing blood clots that can lead to heart attacks or strokes. Bayer has partnered with Ionis Pharmaceuticals, which is developing a blood thinner that is being called a significant improvement over existing therapies. The anti-thrombotic drug is called IONIS-FXIRx, and takes a novel approach to preventing blood clots by inhibiting the production of Factor XI, a ... Read More

First bellwether trial in Xarelto MDL pushed back to April

xarelto

The first bellwether trial in the massive Xarelto multidistrict litigation (MDL) initially scheduled to be tried in in February has been pushed back another month at the request of both plaintiffs and defendants. The first Xarelto bellwether trial was initially set for February in Louisiana’s Eastern District. But with the NBA All-Star game moved to New Orleans and the usual congestion from Mardi Gras, Judge Eldon E. Fallon was prompted to push the start date to March. Now, by agreement of all parties, Judge Fallen has postponed the trials yet another month, to April. The updated schedule is as follows: April 24, ... Read More

Large group of parents claim MiraLAX causes neurological, psychological side effects in children

MiraLAX

The over-the-counter constipation-relieving powder MiraLAX, made by Bayer, can “flip a switch” in the brains of otherwise happy children making them act out bouts of anger, aggression, rage and paranoia, a group of families claim. Their concerns, along with mounting adverse event reports reported to the Food and Drug Administration (FDA), have prompted Children’s Hospital of Philadelphia to launch a study to determine if these parents’ claims have merit. After examining preliminary reserach, it appears the parents’ suspicions may have basis. The FDA stated that MiraLAX powder contains polyethylene glycol 3350 (PEG 3350), an ingredient that may degrade into two ... Read More

Xarelto sales send Bayer profits through the roof

xarelto

Bayer is giving its blockbuster blood thinner Xarelto partial credit for its 2016 drug sales logging a 9 percent year-over-year increase to nearly $17.35 billion. The drug company added that it expects pharmaceutical sales in 2017 to surpass the $18 million mark. Bayer CEO Werner Baumann announced the drug division “achieved substantial sales and earnings increases,” and gave credit for it’s strongest growing products including Xarelto, chemo drug Eylea, hypertension treatment Adempas, and cancer drugs Xofigo and Stivarga. So confident in the performance of these drugs, Bayer raised its combined annual peak sales potential from shy of $8 billion to ... Read More

First Xarelto trial delayed due to NBA All Star game

xarelto

The first bellwether trial in the massive multidistrict litigation (MDL) involving bleeding risks with the blood thinner Xarelto was scheduled to begin this month in the Eastern District of Louisiana, but the National Basketball Association (NBA) All Star game occurring in New Orleans at the same time pushed U.S. District Judge Eldon Fallon to delay trial until March. The Xarelto MDL under Judge Fallon has swelled to nearly 14,000 lawsuits since the it was first consolidated in December 2014. Last summer, Judge Fallon had scheduled the first cases to be tried, with the first to be tried in February. But the ... Read More

Real-world data shows Xarelto has greater bleeding risk than Pradaxa

xarelto

The blockbuster blood thinner Xarelto, prescribed to millions of patients worldwide, may have a higher bleeding risk than its competitor Pradaxa, according to a study based on real-world data published in JAMA Internal Medicine. The study involved records on 118,000 Medicare patients with atrial fibrillation who were treated with either Pradaxa or Xarelto for the prevention of strokes associated with the heart ailment. When compared to patients treated with Pradaxa, the Xarelto group had significant increases in intracerebral hemorrhage, major extracranial bleeding, and gastrointestinal bleeding. Pharmaceuticals are approved for marketing in the U.S. after undergoing a series of clinical trials ... Read More

Xarelto makers test drug on patients with CAD, PAD

xarelto

A study investigating the effectiveness of the blood thinner Xarelto in patients with coronary artery disease (CAD) or peripheral arty disease (PAD) was halted prematurely after an interim analysis showed the medication helped prevent heart attacks, strokes and cardiovascular death. But the study has yet to reveal the rate of bleeding events, a known side effect of Xarelto. CAD and PAD are conditions in which there is a narrowing and blocking of the arteries in various critical regions of the body. CAD affects the heart’s arteries whereas PAD usually affects the arteries in the legs, but can also be used ... Read More

There remains an unmet need for novel anticoagulant reversal agent

xarelto

With the increasing popularity of new novel anticoagulants over the long-used warfarin for the prevention of strokes in atrial fibrillation and other blood clot-related conditions, there remains an unmet need for an antidote to reverse the blood thinning effects of the drugs in the event of a bleeding emergency. The new line of blood thinners were introduced in 2010 and include the direct thrombin inhibitor Pradaxa, and the oral factor Xa inhibitors Xarelto, Eliquis and Savaysa. All anticoagulants increase the risk of major uncontrolled bleeding and life-threatening bleeding events, including gastrointestinal bleeds, rectal bleeds, and brain bleeds. There are currently ... Read More

Risperdal, Xarelto mass tort programs dominate in Pennsylvania court system

risperdal

Only two mass tort programs in Philadelphia’s Complex Litigation Center involving pharmaceuticals grew in 2016: the litigation involving the antipsychotic drug Risperdal and the blood thinner Xarelto. All other pharmaceutical mass torts lost between 6 and 100 percent of their inventory in 2016. As of Jan. 1, 5,601 pharmaceutical cases were pending in Philadelphia – nearly 200 more than were pending at the start of 2012, the year the court started implementing changes designed to clear its mass tort inventory. The Xarelto mass tort grew by 664 cases in 2016, bringing the total of cases pending to 1,214. The program ... Read More